The effect of coenzyme Q10 on atherosclrosis in healthy volunteers

The study on anti-atherosclerosis effects and molecular mechanisms of coenzyme Q10

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003638

Enrollment

Unknown

Registered

2013-09-23

Start date

2011-11-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Interventions

Group A:Placebo capsule, other measures follow the interve

Group B:Coenzyme Q10 capsule, twice a day for 1 week, half an hour after meal to take capsules

Eligibility

Sex/Gender

All

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: 1. Body Mass Index (BMI)<23.0 kg/m2, or males waist<85cmfemale's waist<80cm; 2. Total cholesterol (TC)<5.72mmol/L; 3. Aged between 18 and 30 years; 4. No history of diabetes, acute myocardial infarction, and cerebrovascular accident.

Exclusion criteria

Exclusion criteria: 1. Obvious weight change in the past three months; 2. History of obesity with known cause; 3. Patients with a history of diabetes, an acute myocardial infarction and a stroke; 4. History or evidence of clinically significant liver disease, kidney disease, cancer or uncontrolled thyroid disease; 5. Recent use (within six months) of medications for regulating the level of lipid or blood glucose; 6. Pregnant or breast-feeding woman.

Design outcomes

Primary

Measure	Time frame
Capacity of macrophage cholesterol efflux;HDL inflammatory index;Serum cholesterol efflux potential;Level of lipid;Anthropometric characteristic;	—

Countries

China

Contacts

Public ContactLing Wenhua

Dept.of Nutrition, School of Public Health, Sun Yat-sen University

lingwh@mail.sysu.edu.cn+86 020 87331597

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026